Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Giuseppe A. Palumbo et al.|The Lancet Haematology|2017Cited by 163
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
Vinblastine, bleomycin, and methotrexate chemotherapy plus extended-field radiotherapy in early, favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano per lo Studio dei Linfomi Experience.P. Gobbi, E Ascari, Carla Pieresca et al.|Journal of Clinical Oncology|1996Cited by 26
ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL)Vittorio Silingardi, Caterina Mauri, Massimo Federico et al.|Leukemia & lymphoma/Leukemia and lymphoma|1995Cited by 22
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, TrialEsther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|Blood|2015Cited by 13